NCT07827742尚未招募2 期
Rituximab vs Placebo for Maintenance in Systemic Sclerosis - Interstitial Lung Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- changes in forced vital capacity (FVC) from baseline to Month 18 of randomisation.
研究概览
简要总结
The purpose of this study is to determine whether Rituximab is safe and effective as a maintenance strategy in individuals with stabilized systemic sclerosis in adults.
详细描述
Systemic sclerosis (SSc) is a rare autoimmune connective tissue-disease. Interstitial lung disease (ILD) is a common manifestation and a leading cause of death in SSc.
Rituximab (RTX) is commonly used in SSc-ILD induction treatment and recent trials have now fully demonstrated its safety and efficacy as an induction treatment. The DESIRES trial reported that RTX-induction was associated with a 24-week stabilization of FVC. As evaluated by the FVC at 24 weeks from baseline, 25 patients with SSc-ILD treated with RTX were significantly improved compared with 23 patients treated with placebo (0.09% vs -2.87%; [95%CI 0.08-5.84]; p < 0.05). Recently, the RECITAL trial showed the absence of difference between induction treatment with cyclophosphamide (CYC) and RTX in ILD including SSc-ILD. Indeed, both RTX and CYC resulted in an improvement in FVC (97 ± 234mL and 99 ± 329mL respectively) at 24 weeks, without significant statistical difference in 101 subjects. Furthermore, the EVER-ILD study, also very recently presented, reported a beneficial of RTX in addition to mycophenolate mofetil (MMF) over RTX in CTD-ILD. Altogether with previous European database studies which analyzed the very common usage of RTX as induction therapy in SSc, these studies have confirmed its efficient and safe role as an induction treatment in SSc-ILD.
Still, the impact of re-treatment with RTX in maintaining ILD-stabilization has never been studied and deserve to be studied.
The hypothesis that drives the MAINRITSyS is that RTX maintains ILD stabilization in SSc-ILD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patient (≥ 18 years old),
- •Patient with a diagnosis of SSc, as defined by the ACR/EULAR 2013 criteria (cf. Table 2) (6)
- •Patient with ILD identified on the basis of a HRCT, obtained within 12 months before screening, that showed fibrosis affecting at least 10% of the lungs,
- •SSc-ILD induction with RTX, either twice 1000 mg two weeks apart, or 375 mg/m2 four times 4 weeks apart.
- •The interval between the last induction dose and the first maintenance dose should be 6 months +/- 15 days.
- •Patient with stabilized SSc-ILD following RTX induction treatment as defined by the absence of worsening respiratory symptoms, an absolute decline of FVC of < 5% of the predicted value, an absence of absolute decline of DLCO (corrected for hemoglobin) of < 10% related to SSc-ILD, and absence of radiological evidence of disease progression on HRCT(97)
- •All required vaccinations must have been carried out at least 4 weeks before D
- •According to recommendations, prophylaxis against pneumocystis is recommended for scleroderma, but not mandatory.
- •Woman of childbearing potential should have reliable contraception* for the 12 months' duration of the study's treatment and 12 months after last administration,
- •Patient able to give written informed consent prior to participation in the study,
- •Affiliation to a social security scheme (profit or being entitled). AME is not accepted.
排除标准
- •Forced vital capacity < 40% of the predicted value
- •Diffusion capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) < 30% of the predicted value.
- •Contra-indication or anaphylaxis toward RTX
- •Contra-indication to auxiliary medicinal products
- •Cyclophosphamide, tacrolimus, ciclosporin, or voclosporin during the 2 months prior to screening or during screening
- •Any biologic therapy (including other anti-CD20, anti-CD19, or anti-plasma cell) such as, but not limited to, belimumab, ustekinumab, anifrolumab, secukinumab, or atacicept during the 2 months prior to screening or during screening
- •Inhibitors of Janus-associated kinase (JAK), Bruton's tyrosine kinase (BTK), or tyrosine kinase 2 (TYK2), including baricitinib, tofacitinib, upadacitinib, filgotinib, ibrutinib, or fenebrutinib or any investigational agent during the 2 months prior to screening or during screening
- •Any live vaccine during the 28 days prior to screening or during screening
- •High risk for clinically significant bleeding or any condition requiring plasmapheresis, IV immunoglobulin, or acute blood product transfusions during the 28 days prior the screening
- •Active infection with SARS-CoV-2 or absence of COVID-19 vaccination within the last six months (this criteria will be updated at the time of submission to European Agency to be in adequation with national recommendation at the time of submission).
- •Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude patient participation
- •HIV infection : for participants with unknown HIV status (if the previous tests date more than 3 months), HIV testing will be performed locally at screening.
- •Tuberculosis (TB) infection: Testing for latent TB will be performed locally at screening if required by local regulations or in accordance with local clinical practice. Latent TB after completion of appropriate treatment is not exclusionary
- •Active infection of any kind, excluding fungal infection of the nail beds.
- •History of serious recurrent or chronic infection
- •History of progressive multifocal leukoencephalopathy (PML)
- •History of cancer, including solid tumors, hematological malignancies, and carcinoma in situ, within the past 5 years. Participants with non-melanomatous carcinomas of the skin that have been treated or excised and have resolved are eligible.
- •Major surgery requiring hospitalization during the 4 weeks prior to screening or during screening
- •Current alcohol or drug abuse or history of alcohol or drug abuse within 12 months prior to screening or during screening
- •History of severe allergic or anaphylactic reactions to monoclonal antibodies or known hypersensitivity to any component of the RTX infusion
- •Any of the following laboratory parameters:
- •AST or ALT above 2.5 upper limit normal range
- •Neutrophils <1.5x103/mL
- •Positive hepatitis B surface antigen (HBsAg)
- •Positive hepatitis C serology Participants with positive hepatitis C antibody test result with no detectable hepatitis C virus (HCV) RNA for at least 6 months after completion of antiviral therapy are eligible but will require monthly HCV RNA monitoring until 12 months after the last dose of RTX or placebo.
- •Pregnancy or breastfeeding
- •Participation in another interventional study or being in the exclusion period at the end of a previous study.
- •Participants under court supervision, guardianship, or conservatorship.
研究组 & 干预措施
Placebo
Placebo Comparator
500mg of i.v placebo at M0, M6 and M12
干预措施: Placebo (Drug)
Rituximab
Experimental
500mg of i.v rituximab at M0, M6 and M12
干预措施: Rituximab (Drug)
结局指标
主要结局
changes in forced vital capacity (FVC) from baseline to Month 18 of randomisation.
时间窗: 18 months
PFTs: changes in forced vital capacity (FVC)
次要结局
- Time to death(At 18 months)
- Time to first acute ILD exacerbation(At 18 months)
- Change from baseline in TLC over 6, 12, and 18 months(At 6, 12 and 18 months)
- Hospitalisation for respiratory cause over the duration of the trial(At 18 months)
- Occurrence of AE of specific interest previously mentioned at 6, 12 and 18 months(At 6, 12 and 18 months)
- Change in gammaglobulin, lymphocytes and CD19 levels at 6, 12 and 18 months(At 6, 12 and 18 months)
- Change from baseline in DLCO over 6, 12, and 18 months(At 6, 12 and 18 months)
- Mortality up to 18 months(18 months)
- Occurrence of Adverse Events(At 6, 12 and 18 months)
- Further analyses on TLC(At 6, 12 and 18 months)
- Change from in 6-min walk test distance over 6, 12 and 18 months(At 6, 12 and 18 months)
- Further analyses on FVC(At 6, 12 and 18 months)
- Progression-free survival (composite endpoint of mortality, transplant, treatment failure or decline in FVC >10% compared to baseline) over 6, 12 and 18 months(At 6, 12 and 18 months)
- Treatment failure (as determined by need for transplant or rescue therapy) at 6, 12 and 18 months(At 6, 12 and 18 months)
- INBUILD progression (as determined by the INBUILD criteria for ILD progression(73)) at 6, 12 and 18 months(At 6, 12 and 18 months)
- Change from baseline in capillary oxygen saturation (SpO2) at 6, 12 and 18 months(At 6, 12 and 18 months)
- Changes from baseline to 18 months in HRCT of chest images(At 18 months)
- Proportions of patients who achieved 20%, 30%, 40%, 50% ,60%, 70%, 80%, 90% and 100% response criteria according to revised CRISS at 6, 12 and 18 months(At 6, 12 and 18 months)
- Changes in physicians visual analogue scales over 18 months.(at 0, 6, 12, 18 months)
- Changes in patients' visual analogue scales over 18 months.(At 0, 6, 12, and 18 months)
- Changes in mRSS at 6, 12, and 18 months(At 6, 12 and 18 months)
- Proportion of patients who improved mRSS at 6, 12 and 18 months after randomisation.(At 6, 12 and 18 months)
- Proportion of patients with an active disease according to the European scleroderma trials and research group (EUSTAR) SSc activity index at 6, 12 and 18 months after randomisation(At 6, 12 and 18 months)
- Saint Georges Respiratory Hospital Questionnaire at day 0, and at 6, 12, and 18 months after randomisation.(At 0, 6, 12 and 18 months)
- King Brief's Interstitial Lung Disease questionnaire at day 0, and at 6, 12, and 18 months after randomisation.(at 0, 6, 12, and 18 months)
- Short Form-36 (SF-36) health questionnaire(At 0, 6, 12 and 18 months)
- Time to first hospitalisation for respiratory cause(At 18 months)
- EuroQol-5 Domain (EQ5D5L) health questionnaire(At 0, 6, 12 and 18 months)
- Scleroderma skin patients reported outcome (SSPRO) at day 0, and at 6, 12 and 18 months after randomisation.(At 0, 6, 12 and 18 months)
- HAQ-DI and SHAQ scales at day 0, and at 6, 12 and 18 months after randomisation. These scales range from 0 (minimum) to 3 (maximum) points. Higher score mean worse outcome(At 0, 6, 12 and 18 months)
- Total corticosteroid requirement at 6, 12 and 18 months(At 6, 12 and 18 months)
- Levels of prespecified biomarkers (KL-6, SP-D, MUC1, SFTPD, CCL18 and CXCL4) at months 6, 12 and 18 months.(At 6, 12 and 18 months)
- Presence of anti-RTX-antibody at months 6, 12 and 18.(At 6, 12 and 18 months)
- Dosage of plasma and serum residual concentration of RTX at months 6, 12 and 18(At 6, 12 and 18 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung diseasePatient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%) following RTX induction treatment2025-521331-36-00Assistance Publique Hopitaux De Paris120
尚未招募
2 期
RA-P-OCD-012024-518391-31-00Region Uppsala40
尚未招募
2 期
Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone LymphomaMarginal Zone Lymphoma(MZL)NCT07654465Sun Yat-sen University144
招募中
2 期
Efficacy of rituximab for remission maintenance in patients with primary angiitis of the central nervous system: an open-label, randomized, controlled trial comparing systematic rituximab infusions and azathioprine - MAINRIPACPatients with primary angiitis of the central nervous system2026-525394-39-00Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience74
招募中
3 期
A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022)2023-508015-23-00Merck Sharp & Dohme LLC5